BioCentury
ARTICLE | Clinical News

Bekinda Ondansetron: Phase II started

April 18, 2016 7:00 AM UTC

RedHill began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 12 mg oral Bekinda once daily for 8 weeks in about 120 patients. ...